Compare Stocks: SGMO, TLSA, PMN, and ENGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$1.91	$1.83	$1.40 ▼ $12.25	$127.94M	-0.28	649,337 shs	400,978 shs
PMN Promis Neurosciences	$14.01 +4.1%	$13.89	$6.27 ▼ $27.40	$125.64M	-0.24	39,602 shs	23,986 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A
TLSA Tiziana Life Sciences	$0.91 -6.6%	$1.02	$0.76 ▼ $2.35	$115.25M	0.52	572,802 shs	413,876 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	0.00%	+6.11%	+3.24%	+11.05%	-70.71%
PMN Promis Neurosciences	+4.09%	+3.32%	-4.43%	+32.92%	+23.16%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-57.59%	-85.57%
TLSA Tiziana Life Sciences	-6.64%	-5.67%	-15.36%	-21.93%	-45.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$1.91	$1.83	$1.40 ▼ $12.25	$127.94M	-0.28	649,337 shs	400,978 shs
PMN Promis Neurosciences	$14.01 +4.1%	$13.89	$6.27 ▼ $27.40	$125.64M	-0.24	39,602 shs	23,986 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A
TLSA Tiziana Life Sciences	$0.91 -6.6%	$1.02	$0.76 ▼ $2.35	$115.25M	0.52	572,802 shs	413,876 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	0.00%	+6.11%	+3.24%	+11.05%	-70.71%
PMN Promis Neurosciences	+4.09%	+3.32%	-4.43%	+32.92%	+23.16%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-57.59%	-85.57%
TLSA Tiziana Life Sciences	-6.64%	-5.67%	-15.36%	-21.93%	-45.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENGN enGene	2.14	Hold	$11.05	478.30% Upside
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	142.68% Upside
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest SGMO, TLSA, PMN, and ENGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	ENGN enGene	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/9/2026	ENGN enGene	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/8/2026	PMN Promis Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/8/2026	ENGN enGene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/26/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/12/2026	ENGN enGene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENGN enGene	N/A	N/A	N/A	N/A	$3.44 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.58) per share	N/A
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENGN enGene	-$117.30M	-$1.13	N/A	N/A	N/A	N/A	-27.97%	-22.65%	N/A
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SGMO, TLSA, PMN, and ENGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/8/2026	Q3 2026	ENGN enGene	-$0.4266	-$0.47	-$0.0434	-$0.47	N/A	N/A
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENGN enGene	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENGN enGene	0.11	10.21	10.21
PMN Promis Neurosciences	N/A	7.85	7.85
SGMO Sangamo Therapeutics	N/A	0.84	0.84
TLSA Tiziana Life Sciences	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENGN enGene	64.16%
PMN Promis Neurosciences	50.13%
SGMO Sangamo Therapeutics	56.92%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
ENGN enGene	10.50%
PMN Promis Neurosciences	1.50%
SGMO Sangamo Therapeutics	4.10%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENGN enGene	82	66.99 million	59.95 million	N/A
PMN Promis Neurosciences	11	8.97 million	8.83 million	Not Optionable
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable

SGMO, TLSA, PMN, and ENGN Headlines

Recent News About These Companies

Why is Tiziana Life Sciences stock gaining Thursday?

September 17 at 5:49 PM | msn.com

Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up

September 17 at 12:49 PM | rttnews.com

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

September 17 at 12:25 PM | proactiveinvestors.com

Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

September 17 at 7:48 AM | markets.businessinsider.com

Tiziana Life Sciences consensus price target decreased by 11.11% to $8.16

September 15, 2026 | msn.com

Tiziana Life Sciences (TLSA) to Announce Quarterly Earnings on Friday

September 11, 2026 | americanbankingnews.com

Tiziana Life Sciences (TLSA) Expected to Post Quarterly Earnings on Friday

September 11, 2026 | marketbeat.com

BTIG initiates coverage of Tiziana Life Sciences (TLSA) with buy rating

September 3, 2026 | msn.com

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

September 3, 2026 | proactiveinvestors.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.9% - Should You Sell?

August 28, 2026 | marketbeat.com

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

August 24, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

August 24, 2026 | globenewswire.com

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Acquires $81,292.79 in Stock

August 7, 2026 | insidertrades.com

Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $667,000.00 in Stock

August 6, 2026 | insidertrades.com

Tiziana Life Sciences Ltd.: Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

August 2, 2026 | finanznachrichten.de

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

July 31, 2026 | benzinga.com

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

July 31, 2026 | proactiveinvestors.com

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

July 31, 2026 | finance.yahoo.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock, Short Interest Report

July 13, 2026 | benzinga.com

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

June 25, 2026 | proactiveinvestors.com

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

June 25, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, TLSA, PMN, and ENGN Company Descriptions

enGene NASDAQ:ENGN

$1.91 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.91 0.00 (-0.21%)

As of 09/18/2026 07:50 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Promis Neurosciences NASDAQ:PMN

$14.01 +0.55 (+4.09%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.00 -0.02 (-0.11%)

As of 09/18/2026 07:37 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 09/18/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Tiziana Life Sciences NASDAQ:TLSA

$0.91 -0.06 (-6.64%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.90 0.00 (-0.07%)

As of 09/18/2026 07:40 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMO, TLSA, PMN, and ENGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMO, TLSA, PMN, and ENGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMO, TLSA, PMN, and ENGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, TLSA, PMN, and ENGN Company Descriptions

enGene NASDAQ:ENGN

Promis Neurosciences NASDAQ:PMN

Sangamo Therapeutics NASDAQ:SGMO

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMO, TLSA, PMN, and ENGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMO, TLSA, PMN, and ENGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMO, TLSA, PMN, and ENGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, TLSA, PMN, and ENGN Company Descriptions

enGene NASDAQ:ENGN

Promis Neurosciences NASDAQ:PMN

Sangamo Therapeutics NASDAQ:SGMO

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools